Innovative Industrial Properties (IIPR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
2025 saw disciplined execution, prudent capital stewardship, and strategic positioning for long-term stockholder value, with $266 million in total revenues and $205 million in AFFO, and nearly $200 million in cash flows from operations.
Over $1.1 billion has been returned to stockholders via dividends since inception, with a 39% CAGR in dividends per share from 2017 to 2025.
The company maintains a conservative capital structure, with a debt service coverage ratio over 10x and net debt to adjusted EBITDA of 1.4x, and over $2 billion in unencumbered real estate.
Strategic capital deployment included $275 million in real estate and life science investments, notably in IQHQ, enhancing diversification and resilience.
Liquidity was strengthened by raising $100 million under a new revolving credit facility and issuing $24 million of preferred stock.
Tenant base repositioning led to 339,000 square feet of new leasing activity, improving cash flow quality.
Voting matters and shareholder proposals
Stockholders will vote on: election of five directors, ratification of BDO USA, P.C. as auditor, approval of the 2026 Omnibus Incentive Plan, advisory vote on executive compensation, and advisory vote on frequency of executive compensation votes.
Board recommends voting FOR all proposals and for annual (one-year) say-on-pay frequency.
Board of directors and corporate governance
Board consists of five members, majority independent, with all committees composed of independent directors.
Directors are subject to annual election, minimum stock ownership requirements, and a formal clawback policy.
Board conducts annual self-evaluations and succession planning, and encourages diversity in future nominations.
No stockholder rights plan is in effect; bylaws allow stockholder amendments.
Latest events from Innovative Industrial Properties
- Q1 2026 revenue was $69M, but tenant defaults and debt maturity threaten ongoing viability.IIPR
Q1 20265 May 2026 - Diversified REIT with robust growth, strong balance sheet, and expanding life sciences exposure.IIPR
Investor presentation5 May 2026 - 2025 revenues hit $266M; life sciences investment and leasing drive growth amid tenant challenges.IIPR
Q4 202524 Feb 2026 - Q2 revenue up 4% to $79.8M, AFFO $2.29/share, 95.6% leased, and dividend up 4.4%.IIPR
Q2 20242 Feb 2026 - Q3 2024 revenue was $76.5M, AFFO $64.3M, and portfolio was 95.7% leased.IIPR
Q3 202415 Jan 2026 - 2024 revenue steady at $308.5M; strong liquidity, high occupancy, and PharmaCann lease resolution.IIPR
Q4 202423 Dec 2025 - 2024 saw record revenue, strong governance, and enhanced ESG and compensation practices.IIPR
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with board support for all.IIPR
Proxy Filing1 Dec 2025 - Q1 2025 revenue and net income fell on tenant defaults, but liquidity and leasing remain strong.IIPR
Q1 202524 Nov 2025